The independent platform for news, articles and advice for professionals in laboratory medicine

Fighting Alzheimer’s disease: setting a new standard in blood biomarker innovation

C2N Diagnostics says it further bolstered its role as a leader in advanced brain health diagnostics at the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam. The presentations included information on the company’s pipeline product, PrecivityAD2, along with other Precivity-related analytes that are setting a new standard in blood biomarker innovation and diagnostic performance.

The company’s next-generation product, PrecivityAD2, due for imminent release. is designed to help healthcare providers determine the presence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease (AD), by using proprietary mass spectrometry technology.

These developments occur as the National Institute on Aging and the Alzheimer’s Association look to update their diagnostic criteria to incorporate blood biomarkers for the first time so healthcare providers can use them to identify amyloid plaques in the brain, a hallmark indicator of Alzheimer’s disease. The workgroup is currently collecting feedback and suggestions about the draft guidelines.

C2N CEO Dr Joel Braunstein noted that the developments at AAIC occur along with the fact that Eisai used C2N’s assay in its clinical trial for the recently approved LEQEMBI for Alzheimer’s disease  treatment. “These activities demonstrate C2N’s blood biomarkers have been principal blood biomarkers to demonstrate biological evidence of clinically-relevant disease modification with anti-amyloid therapeutic antibodies. This positioning will continue to grow and be very helpful as diagnostic guidelines reflect these innovations and recognise their availability for use in clinical care.

It’s a privilege for our biomarkers to be incorporated into landmark treatment studies that are changing how patients with early AD will be managed. We believe these data, combined with primary care data further bolster the company’s position as the preferred partner in brain health diagnostics to work alongside healthcare providers in improving patient care and to advance clinical research of new treatment options for patients.”

Upcoming Events

Digital Pathology & AI Congress: Europe

The Intercontinental London Hotel, The O2, London SE10 0TW
7-8 December

POCT Innovators: The Power to Disrupt Series

Cloth Hall Court, Leeds. UK
20 March, 2024

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

Royal Air Force Museum, Hendon, London
2 May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Digital Pathology & AI Congress: Europe

The Intercontinental London Hotel, The O2, London SE10 0TW
7-8 December

POCT Innovators: The Power to Disrupt Series

Cloth Hall Court, Leeds. UK
20 March, 2024

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

Royal Air Force Museum, Hendon, London
2 May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2023 Step Communications Ltd. Registered in England. Registration Number 3893025